Sign in

CIK 0001590877

  • Non-accelerated filer
  • Smaller reporting company

REGENXBIO Inc.

Sign in to watch
Ticker
RGNX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
471851754
Phone
+1 240-552-8181
Business address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Former names
ReGenX Biosciences, LLC
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Open-market sale SVP, Product Development & CTO sold 18,000 shares at $50.00 ($900,000)
  9. 4 Open-market sale President and CEO sold 15,000 shares at an average $42.99 ($644,866)
  10. 4 Open-market sale President and CEO sold 15,000 shares at an average $50.44 ($756,566)
  11. 4 Open-market sale SVP, General Counsel sold 5,000 shares at an average $53.23 ($266,161)
  12. 4 Derivatives Options or other derivatives
  13. 3 Insider Initial Statement of Ownership
  14. 4 Open-market sale Chief Scientific Officer sold 2,000 shares at an average $52.66 ($105,320)
  15. 4 Open-market sale Chief Financial Officer sold 10,000 shares at an average $60.75 ($607,539)
  16. 4 Open-market sale President and CEO sold 15,000 shares at an average $58.53 ($877,989)
  17. 4 Exercise or conversion Chief Scientific Officer acquired 5,000 shares (option exercise)
  18. 4 Open-market sale Chief Financial Officer sold 3,068 shares at $60.01 ($184,111)
  19. 4 Open-market sale SVP, Product Development & CTO sold 5,300 shares at $54.05 ($286,465)
  20. 4 Open-market sale President and CEO sold 15,000 shares at an average $47.29 ($709,284)

Page 12 of 22 · 435 filings